159 related articles for article (PubMed ID: 28949997)
41. Chronic Chagas disease with advanced cardiac complications in Japan: Case report and literature review.
Imai K; Maeda T; Sayama Y; Osa M; Mikita K; Kurane I; Miyahira Y; Kawana A; Miura S
Parasitol Int; 2015 Oct; 64(5):240-2. PubMed ID: 25744336
[TBL] [Abstract][Full Text] [Related]
42. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis.
Pérez-Molina JA; Pérez-Ayala A; Moreno S; Fernández-González MC; Zamora J; López-Velez R
J Antimicrob Chemother; 2009 Dec; 64(6):1139-47. PubMed ID: 19819909
[TBL] [Abstract][Full Text] [Related]
43. Prevention of congenital Chagas through treatment of girls and women of childbearing age.
Moscatelli G; Moroni S; García-Bournissen F; Ballering G; Bisio M; Freilij H; Altcheh J
Mem Inst Oswaldo Cruz; 2015 Jun; 110(4):507-9. PubMed ID: 25993401
[TBL] [Abstract][Full Text] [Related]
44. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy.
Bustamante JM; Presti MS; Rivarola HW; Fernández AR; Enders JE; Fretes RE; Paglini-Oliva P
Int J Antimicrob Agents; 2007 Jun; 29(6):733-7. PubMed ID: 17395432
[TBL] [Abstract][Full Text] [Related]
45. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
Gallerano RR; Sosa RR
Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
[TBL] [Abstract][Full Text] [Related]
46. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country.
González-Ramos J; Noguera-Morel L; Tong HY; Ramírez E; Ruiz-Bravo E; Bellón T; Cabañas R; Cachafeiro L; Herranz-Pinto P
Br J Dermatol; 2016 Sep; 175(3):604-7. PubMed ID: 26851874
[TBL] [Abstract][Full Text] [Related]
47. Difference of effective antitrypanosomal dosages of benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results.
Richle RW; Raaflaub J
Acta Trop; 1980 Sep; 37(3):257-61. PubMed ID: 6106364
[No Abstract] [Full Text] [Related]
48. Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers.
Molina I; Salvador F; Sánchez-Montalvá A; Treviño B; Serre N; Sao Avilés A; Almirante B
Antimicrob Agents Chemother; 2015 Oct; 59(10):6125-31. PubMed ID: 26195525
[TBL] [Abstract][Full Text] [Related]
49. Reporting of adverse reactions to benznidazole: does medical expertise matter?
Pereiro AC; Lenardón M; Zeballos A; Chopita M; Abril M; Gold S
Rev Panam Salud Publica; 2018; 42():e69. PubMed ID: 31093097
[TBL] [Abstract][Full Text] [Related]
50. [Postpartum treatment without interrupting breastfeeding in a patient with Chagas disease].
Vela-Bahena LE; Vergara R; Vite L; Ramos C
Ginecol Obstet Mex; 2015 Aug; 83(8):487-93. PubMed ID: 26591033
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of chronic Chagas' disease. Is the etiological treatment effective?].
Rassi A; Rassi Júnior A
Arq Bras Cardiol; 1998 Oct; 71(4):643-6. PubMed ID: 10347944
[No Abstract] [Full Text] [Related]
52. Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.
Hasslocher-Moreno AM; Saraiva RM; Sangenis LHC; Xavier SS; de Sousa AS; Costa AR; de Holanda MT; Veloso HH; Mendes FSNS; Costa FAC; Boia MN; Brasil PEAA; Carneiro FM; da Silva GMS; Mediano MFF
EClinicalMedicine; 2021 Jan; 31():100694. PubMed ID: 33554085
[TBL] [Abstract][Full Text] [Related]
53. The in vivo trypanocidal effect of the diterpene 5-epi-icetexone obtained from Salvia gilliesii.
Lozano E; Strauss M; Spina R; Cifuente D; Tonn C; Rivarola HW; Sosa MA
Parasitol Int; 2016 Feb; 65(1):23-26. PubMed ID: 26341064
[TBL] [Abstract][Full Text] [Related]
54. Benznidazole prevents endothelial damage in an experimental model of Chagas disease.
Molina-Berríos A; Campos-Estrada C; Lapier M; Duaso J; Kemmerling U; Galanti N; Leiva M; Ferreira J; López-Muñoz R; Maya JD
Acta Trop; 2013 Jul; 127(1):6-13. PubMed ID: 23529066
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.
Fabbro D; Velazquez E; Bizai ML; Denner S; Olivera V; Arias E; Pravia C; Ruiz AM
Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740013
[TBL] [Abstract][Full Text] [Related]
56. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
[TBL] [Abstract][Full Text] [Related]
57. Update in treatment of Chagas disease.
Le Loup G; Pialoux G; Lescure FX
Curr Opin Infect Dis; 2011 Oct; 24(5):428-34. PubMed ID: 21857512
[TBL] [Abstract][Full Text] [Related]
58. Treatment of experimental chronic chagas disease with trifluralin.
Zaidenberg A; Luong T; Lirussi D; Bleiz J; Del Buono MB; Quijano G; Drut R; Kozubsky L; Marron A; Buschiazzo H
Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):351-6. PubMed ID: 16623857
[TBL] [Abstract][Full Text] [Related]
59. A high-performance liquid chromatographic method for benznidazole quantitation in plasma of patients with Chagas disease.
Guerrero L; Pinazo MJ; Posada E; Gascón J; Ribas J; Soy D
Clin Chem Lab Med; 2011 Jan; 49(1):77-82. PubMed ID: 21083440
[TBL] [Abstract][Full Text] [Related]
60. Chagas seropositive donors in kidney transplantation.
Sousa AA; Lobo MC; Barbosa RA; Bello V
Transplant Proc; 2004 May; 36(4):868-9. PubMed ID: 15194296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
